


# ALASKA BPM Conversation with Stakeholder Committee

March 31 , 2006

Sandra L. Forquer, Ph. D. Bruce Gorman, MCRP

© 2006 Comprehensive NeuroScience, Inc. Reprints and Distribution Prohibited




### BPM Results 2/05 through 11/05

- Selected Patient Data
- Selected Prescriber Data
- Selected Executive Management Report Data
- Group Discussion



### Quality Indicator: Children on 3 or More Psychotropics


■ The number of patients associated with this indicator decreased from 342 to 149 (56%).





### Quality Indicator: Adults on 5 or More Psychotropics


■ The number of patients associated with this indicator decreased from 147 to 70 (52%).





# Quality Indicator: Multiple Prescribers of Any Class of Drugs


■ The number of patients associated with this indicator decreased from 452 to 172 (62%).





# Quality Indicator: Low Dose Use of Atypical Antipsychotics


■ The number of patients associated with this indicator decreased from 417 to 136 (67%).





# Quality Indicator: Polypharmacy (various drug classes)


■ The number of prescribers associated with this indicator decreased from 68 to 28 (59%).





# Quality Indicator: High Dose Use of Atypical Antipsychotics

■ The number of prescribers associated with this indicator decreased from 89 to 53 (40%).






### Variance between Expected and Actual Monthly Behavioral Rx Claims Spend

### **Executive Management Report**

Alaska May 2004 - November 2005



Note: Monthly average % change is 1.2% prior to First Intervention.

Note: Descriptive data – not intended as a measure of CNS' intervention





### Decrease in Monthly Behavioral Rx Claims

### **Executive Management Report**

Alaska

May 2004 - November 2005





--- Orientation Mailing

- First Intervention

Note: % change based on numbers at First Intervention and Current Month Note: Descriptive data – not intended as a measure of CNS' intervention




### Smaller Increase in Monthly Behavioral Rx Cost per Patient for "Targeted Patients"

### **Executive Management Report**

Alaska

May 2004 - November 2005



-- - · Orientation Mailing

First Intervention

Note: % change prior to First Intervention based on August 2004 and May 2005 numbers Note: % change after First Intervention based on May 2005 and Current month numbers

Note: Descriptive data - not intended as a measure of CNS' intervention



### **Update on BPM '06**

- Selected New Quality Indicators: Child/Adolescents and Adults
- Selected Quality Indicator Preliminary Data
- Review of Sample Prescriber Packets
- Feedback and Suggestions




### BPM '06 Selected Child/Adolescent Data (11-1-05 through 1-31-06)

- Use of 5 or More Psychotropics During a 90 Day Period (Under 18 Years): 86 patients, 56 prescribers
- Use of 2 or More Antipsychotics for 45 or More Days (Under 18 Years): 43 patients, 27 prescribers
- Use of an Antipsychotic at Higher Than Recommended Dose for 45 or More Days (Under 18 Years): 119 patients, 55 prescribers
- Failure to Refill a Newly Prescribed Stimulant or ADHD Non-Stimulant within 30 Days of RX Ending (Under 18 years): 54 patients, 28 prescribers



### BPM '06 Selected Adult Data (11-1-05 through 1-31-06)

- Use of an Atypical Antipsychotic at a Higher Than Recommended Dose for 45 or More Days: 120 patients, 53 prescribers
- Use of 1 or More Benzodiazepines and 1 or More Antidepressants for 60 Days or More: 228 patients, 192 prescribers
- Failure to Refill a Newly Prescribed
  Antidepressant Within 30 Days of Prescription:
  212 patients, 123 prescribers
- Multiple Prescribers of Same Class of Psychotropic Drug for 45 or More Days: 57 patients, 112 prescribers



### Launch BPM '06

- Mail orientation letter (completed)
- Mail to Child and Adolescent Prescribers (completed)
- Mail to Adult Prescribers (completed shortly)
- **Enhance Peer Consulting Program**
- Revisit Quality Indictors<sup>™</sup> to Message On



